

## New FDG PET Medicare Item - Initial staging of eligible cancer types

From 1 November 2022 a new item is available for initial staging by FDG-PET of rare or uncommon cancer types, meeting certain criteria as below.

This item can only be requested by a specialist or consultant physician and adequate clinical information has to be **recorded on the request form** to match the below criteria.

### FDG PET – initial staging of rare or uncommon cancers

#### ITEM NUMBER - 61612

Whole body FDG PET study for the initial staging of eligible cancer types for a patient who is considered suitable for active therapy, IF:

- a) The eligible cancer types is:
  - i. A rare or uncommon cancer (less than 12 cases per 100,000 persons per year\*); AND
  - ii. A typically FDG-avid cancer; AND
- b) There is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient.

**Applicable once per cancer diagnosis.**

For our PET/CT locations and billing information – [www.qldxray.com.au/billingguide](http://www.qldxray.com.au/billingguide)

\* list of cancer types considered rare or uncommon

Anal cancer	Bladder cancer	Brain and other central nervous system
Brain cancer	Gallbladder and extrahepatic bile ducts	Gastrointestinal stromal tumours (GIST)
Kaposi sarcoma	Liver cancer	Merkel cell cancer
Mesothelioma	Multiple myeloma	Ovarian cancer (incidence only)
Ovarian cancer and serious carcinomas of the fallopian tube	Pancreatic cancer	Penile cancer
Peritoneal cancer	Placenta cancer	Small cell lung cancer
Small intestine	Stomach cancer	Testicular cancer
Thyroid cancer	Unknown primary site	Uterine cancer
Vaginal cancer	Vulvar cancer	